- Home
- HCC vs HRMY Comparison
HCC vs HRMY Comparison
Compare HCC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- HRMY
- Stock Information
- Founded
- HCC 2015
- HRMY 2017
- Country
- HCC United States
- HRMY United States
- Employees
- HCC N/A
- HRMY N/A
- Industry
- HCC Coal Mining
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- HRMY Health Care
- Exchange
- HCC Nasdaq
- HRMY Nasdaq
- Market Cap
- HCC 2.3B
- HRMY 2.0B
- IPO Year
- HCC 2017
- HRMY 2020
- Fundamental
- Price
- HCC $44.38
- HRMY $31.95
- Analyst Decision
- HCC Strong Buy
- HRMY Strong Buy
- Analyst Count
- HCC 5
- HRMY 9
- Target Price
- HCC $70.25
- HRMY $54.22
- AVG Volume (30 Days)
- HCC 998.8K
- HRMY 661.5K
- Earning Date
- HCC 07-31-2025
- HRMY 08-05-2025
- Dividend Yield
- HCC 0.72%
- HRMY N/A
- EPS Growth
- HCC N/A
- HRMY 13.13
- EPS
- HCC 2.01
- HRMY 2.62
- Revenue
- HCC $1,319,451,000.00
- HRMY $744,852,000.00
- Revenue This Year
- HCC N/A
- HRMY $20.10
- Revenue Next Year
- HCC $33.59
- HRMY $18.01
- P/E Ratio
- HCC $22.04
- HRMY $12.20
- Revenue Growth
- HCC N/A
- HRMY 20.62
- 52 Week Low
- HCC $38.00
- HRMY $26.47
- 52 Week High
- HCC $75.53
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- HCC 47.90
- HRMY 44.85
- Support Level
- HCC $40.80
- HRMY $31.25
- Resistance Level
- HCC $47.03
- HRMY $32.32
- Average True Range (ATR)
- HCC 1.89
- HRMY 0.98
- MACD
- HCC -0.09
- HRMY -0.19
- Stochastic Oscillator
- HCC 54.45
- HRMY 21.37
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.